Andere Sprachen Quince Therapeutics, Inc.

Aktien

A2PHHD

US22053A1079

QNCX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.06.2024			% 5 Tage	% 1. Jan.
0,6875 ^USD	-2,48 %		+1,10 %	-34,52 %

25.06.	Quince Therapeutics verabreicht ersten Patienten in Phase-3-Studie von EryDex zur Behandlung von Ataxia-Telangiectasia	MT
25.06.	Quince Therapeutics gibt die Verabreichung des ersten Patienten in der klinischen Phase-3-Studie mit Erydex zur Behandlung von Ataxia-Telangiectasia bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia	25.06.
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia	25.06.
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of Erydex for the Treatment of Ataxia-Telangiectasia	25.06.
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System	03.06.
Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System	03.06.
Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	13.05.
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference	06.05.
Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results	01.04.
North American Morning Briefing : Markets Steady -2-	26.03.
Quince Therapeutics Launches Scientific Advisory Board	22.02.
Quince Therapeutics, Inc. Launches Scientific Advisory Board	22.02.
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors	15.02.
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors	15.02.
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	07.02.
Quince Therapeutics to Participate at Investor Events in January 2024	04.01.
North American Morning Briefing : All Eyes on -2-	21.11.
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Quince Therapeutics : Investor Presentation – November 2023	06.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Quince Therapeutics, Inc.

Aktien

A2PHHD

US22053A1079

QNCX

Andere Sprachen

Filter